Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO^® in the mainland of China, broadening coverage and improving access of the drug to patients in the mainland of China

-      Antengene to receive up to RMB200 million in upfront payments, and up to RMB535 million in milestone payments from Hansoh Pharma

-      XPOVIO^® is approved in the mainland of China for relapsed/refractory multiple myeloma. Antengene plans to submit supplemental new drug application (sNDA) for XPOVIO^® as a monotherapy for the treatment of adult patients with relapsed /refractory diffuse large B-cell lymphoma in Q3 2023, and in combination for the treatment of adult patients with multiple myeloma who have received at least one prior therapy in H1 2024

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, and Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma" SEHK: 3692.HK), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases, and autoimmune diseases, announced today the entrance into a collaboration agreement between Antengene and Hansoh Pharma for the commercialization of XPOVIO^® in the mainland of China.

"Our collaboration with Hansoh Pharma further strengthens our confidence in the market potential of the First and Only-in-class XPO1 inhibitor XPOVIO^® in the mainland of China," said Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene. "Through collaborating with Hansoh Pharma, we will leverage their well-established commercialization infrastructure to make XPOVIO^® more accessible to patients in the mainland of China. Given Antengene's plans to apply for inclusion into the National Reimbursement Drug List (NRDL) for XPOVIO^® in the near future, and the broad indication expansion potential of XPOVIO^®, it is crucial to ensure that XPOVIO^® could reach as many cities, hospitals and prescribers, and benefit as many patients as possible.  We believe this collaboration with Hansoh Pharma will not only enhance assess of XPOVIO^® but also lead to commercial success in the mainland of China."

"Hansoh Pharma is excited to enter into this partnership with Antengene and is committed to bringing XPOVIO^® to more patients in China," said Ms. Yuan Sun, Executive Director of Hansoh Pharma. "We believe that XPOVIO^® is a drug with great commercial potential, addressing huge unmet medical needs for those hematologic patients in China.  In addition to obtaining approvals in multiple countries and regions globally for multiple myeloma and diffuse large B-cell lymphoma, XPOVIO^® has indication expansion potential in myelofibrosis, endometrial cancer, as well as T/NK-cell lymphoma.  We look forward to collaborating with Antengene and make XPOVIO^® available to the widest possible number of Chinese patients with hematological malignancies."

Under the terms of the agreement, Antengene will continue to be responsible for research and development, regulatory approvals and affairs, product supply, and distribution of XPOVIO^®, while Hansoh Pharma will be exclusively responsible for commercialization of XPOVIO^® in the mainland of China. Antengene will receive up to RMB200 million of upfront payments, RMB100 million of which shall be received upon signing, and pursuant to the Agreement and subject to the terms and conditions thereof, Antengene shall be eligible to receive up to RMB100 million of the remaining upfront payments, and up to RMB535 million in milestone payments from Hansoh Pharma. Antengene will continue to record revenues from sales of XPOVIO^® in the mainland of China and Hansoh Pharma will charge a service fee to Antengene.